This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Carvedilol
From Proteopedia
(Difference between revisions)
| (7 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
| - | <StructureSection load='' size='340' side='right' caption=' | + | <StructureSection load='' size='340' side='right' caption='Carvedilol' scene='10/1009520/Cv/2'> |
Carvedilol, sold under the brand name Coreg among others, is a medication used to treat high blood pressure, congestive heart failure (CHF), and left ventricular dysfunction in people who are otherwise stable. For high blood pressure, it is generally a second-line treatment.<ref name="a1">[https://www.drugs.com/monograph/carvedilol.html "Carvedilol Monograph for Professionals".] Drugs.com. AHFS. Retrieved 24 December 2018.</ref> See also [https://en.wikipedia.org/wiki/Carvedilol Carvedilol]. | Carvedilol, sold under the brand name Coreg among others, is a medication used to treat high blood pressure, congestive heart failure (CHF), and left ventricular dysfunction in people who are otherwise stable. For high blood pressure, it is generally a second-line treatment.<ref name="a1">[https://www.drugs.com/monograph/carvedilol.html "Carvedilol Monograph for Professionals".] Drugs.com. AHFS. Retrieved 24 December 2018.</ref> See also [https://en.wikipedia.org/wiki/Carvedilol Carvedilol]. | ||
| + | Carvedilol is both a non-selective β-adrenergic receptor antagonist (β1, β2) and an α-adrenergic receptor antagonist (α1). See also [[Adrenergic receptor]]. The S(–) enantiomer accounts for the beta-blocking activity whereas the S(–) and R(+) enantiomers have alpha-blocking activity.<ref name="a15">[https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020297s029lbl.pdf "Coreg - Food and Drug Administration"] (PDF).</ref> The affinity (Ki) of carvedilol for the β-adrenergic receptors is 0.32 nM for the human β1-adrenergic receptor and 0.13 to 0.40 nM for the β2-adrenergic receptor.<ref name="a22">[https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=biology&ligandId=551 "Carvedilol | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY"]</ref> | ||
| + | |||
| + | <scene name='10/1009520/Overall/1'>Turkey beta1 adrenergic receptor and bound biased agonist carvedilol</scene> ([[4amj]]). | ||
| + | |||
| + | <scene name='10/1009520/Binding_site/1'>Carvedilol binding site</scene>. | ||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Current revision
| |||||||||||
References
- ↑ "Carvedilol Monograph for Professionals". Drugs.com. AHFS. Retrieved 24 December 2018.
- ↑ "Coreg - Food and Drug Administration" (PDF).
- ↑ "Carvedilol | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY"
